Stoke Therapeutics (NASDAQ:STOK) Given New $47.00 Price Target at HC Wainwright

Stoke Therapeutics (NASDAQ:STOK) had its price objective boosted by HC Wainwright from $35.00 to $47.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms also recently issued reports on STOK. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. Finally, Chardan Capital began coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Stock Performance

STOK stock opened at $9.71 on Tuesday. The firm has a market cap of $514.34 million, a price-to-earnings ratio of -4.62 and a beta of 0.95. The firm has a 50-day simple moving average of $10.84 and a two-hundred day simple moving average of $12.40. Stoke Therapeutics has a one year low of $5.14 and a one year high of $17.58.

Insider Buying and Selling

In other news, General Counsel Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $123,914.88. Following the completion of the transaction, the general counsel now owns 35,142 shares in the company, valued at approximately $449,114.76. This trade represents a 21.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Barry Ticho sold 2,586 shares of Stoke Therapeutics stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $12.99, for a total value of $33,592.14. Following the completion of the transaction, the insider now owns 44,746 shares of the company’s stock, valued at $581,250.54. The trade was a 5.46 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics during the fourth quarter worth approximately $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics during the fourth quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. acquired a new position in Stoke Therapeutics during the fourth quarter worth approximately $124,000. Tower Research Capital LLC TRC increased its position in Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after buying an additional 4,918 shares during the period. Finally, Invesco Ltd. acquired a new position in Stoke Therapeutics during the fourth quarter worth approximately $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.